Bristol-Myers Squibb (United Kingdom)
In research, Bristol-Myers Squibb (United Kingdom) stands highest in Medicine (#7,630 of 10,443 worldwide) and Health Sciences (#9,376 of 11,982 worldwide), 2022–2025. Relative to its size it is most specialised in Economics and Econometrics and Economics, Econometrics and Finance — Economics and Econometrics is 9.4× its share of world research.
- World rank, 2022–2025
- #15,606 of 28,054 · #19,756 all time
- Rank in United Kingdom
- #564 of 1,094
- Research works
- 453 ▲ 97% vs 2013–17
- Citations
- 7.6k 16.8 per fractional work
- Top-10% rate
- 10.9% record average 16.5%
- Open access
- 40% world 28%
What is Bristol-Myers Squibb (United Kingdom) known for in research?
The fields where it stands highest, 2022–2025, ranked among every institution above the floor in each field.
| Field | World rank | Where that sits | Top-10% rate | Works | All time |
|---|---|---|---|---|---|
| MedicineField | #7,630 of 10,443 | 9.2% | 68 | #9618 | |
| Health SciencesDomain | #9,376 of 11,982 | 9.1% | 71 | #11529 |
Each strip is that field’s whole ranked pool, with the notch where Bristol-Myers Squibb (United Kingdom) sits in it, in the colour of the band that rank falls in. The track under the rate is the rate itself: it carries no world mark, because the world rate differs by field (from about 6% to 21% in this record).
What does Bristol-Myers Squibb (United Kingdom) specialise in?
Where its research is concentrated relative to its size: Economics and Econometrics takes 9.4× the share of its output that it takes of world research.
- Economics and EconometricsSubfield · 20.6 works9.4×
- Economics, Econometrics and FinanceField · 20.8 works7.0×
Location quotient, a volume reading rather than an impact one. It surfaces small, lopsided specialities.
Field profile
Location quotient across every field it publishes in: outside the ring is more than an institution of this size would be expected to publish, inside it is less.
Rings at 0.5×, 1× and 2×. Widest outward: Economics, Econometrics and Finance, 7.0×. Every wedge is a field page.
- Economics, Econometrics and Finance 7.0×
- Pharmacology, Toxicology and Pharmaceutics 5.0×
- Chemistry 4.3×
- Medicine 2.5×
- Mathematics 1.7×
- Decision Sciences 1.6×
- Biochemistry, Genetics and Molecular Biology 1.4×
- Immunology and Microbiology 1.4×
- Chemical Engineering 1.1×
- Health Professions 0.8×
- Computer Science 0.6×
- Energy 0.4×
- Materials Science 0.3×
- Engineering 0.3×
- Dentistry 0.3×
- Nursing 0.2×
- Environmental Science 0.1×
- Veterinary 0.1×
- Earth and Planetary Sciences 0.1×
- Physics and Astronomy 0.1×
- Social Sciences 0.1×
- Neuroscience 0.1×
- Psychology 0.1×
- Agricultural and Biological Sciences 0.0×
- Business, Management and Accounting 0.0×
Who are the top researchers at Bristol-Myers Squibb (United Kingdom)?
Ranked on the composite score, Sreeram V Ramagopalan, Robert Carroll and James Chadwick lead among researchers whose main affiliation is Bristol-Myers Squibb (United Kingdom).
- 1 Sreeram V Ramagopalan United Kingdom · #144,551 worldwide 152 citations · 36 works
- 2 Robert Carroll United Kingdom · #711,210 worldwide 41 citations · 19 works
- 3 James Chadwick United Kingdom · #796,249 worldwide 91 citations · 53 works
- 4 Bill Malcolm United Kingdom · #855,376 worldwide 110 citations · 75 works
- 5 Peter Timmins United Kingdom · #862,410 worldwide 88 citations · 40 works
Which keywords describe research at Bristol-Myers Squibb (United Kingdom)?
By fractional works in 2022–2025, weighted toward what it does more of than the world: Immunotherapy, Chemotherapy, Cost-effectiveness Analysis, Health Utility Measures, Quality of Life, Neoadjuvant Therapy, Tumor Microenvironment and Molecular Characterization.
- Esophageal Carcinoma
- Chemoradiation
- Preoperative Chemoradiotherapy
- Lymphoma
- Monoclonal Antibodies
- ALK Inhibitors
- Dilated Cardiomyopathy
- Meta-Analysis
- Urothelial Carcinoma
- Bladder Cancer
- Endoscopic Resection
- Treatment
- Clinical Trials
- Immune Checkpoint Blockade
- Financial Toxicity
- Guidelines
- Tumor Microenvironment
- Epidemiology
- Cost-effectiveness Analysis
- Quality of Life
- Immunotherapy
- Chemotherapy
- Health Utility Measures
- Neoadjuvant Therapy
- Molecular Characterization
- Cost of Care
- Genetic Mutations
- PD-1 and PD-L1
- Targeted Therapy
- Prognostic Factors
- Precision Medicine
- Genomic Profiling
- Cardiac Imaging
- Cardiomyopathies
- Myosin
- EGFR Mutations
- Heart Failure
- Adjuvant Therapy
- Tumor Staging
- Barrett's Esophagus
Size is fractional works in 2022–2025 in the topics tagged with each word; colour is the word's share of this institution's work against its share of the world's. The 40 words are chosen for being large and distinctive. Each links to the topic it comes from most.
All 40 words, with their numbers
- Immunotherapy13▲ 13×12 topics
- Quality of Life10▲ 5.3×7 topics
- Chemotherapy10▲ 10×11 topics
- Cost-effectiveness Analysis10▲ 82×1 topic
- Health Utility Measures10▲ 82×1 topic
- Epidemiology9▲ 1.65×23 topics
- Neoadjuvant Therapy8▲ 25×4 topics
- Tumor Microenvironment8▲ 13×6 topics
- Molecular Characterization8▲ 31×4 topics
- Guidelines7▲ 11×5 topics
- Cost of Care7▲ 164×1 topic
- Financial Toxicity7▲ 164×1 topic
- Genetic Mutations7▲ 11×6 topics
- Immune Checkpoint Blockade6▲ 43×1 topic
- PD-1 and PD-L16▲ 43×1 topic
- Clinical Trials6▲ 6.5×8 topics
- Targeted Therapy6▲ 19×4 topics
- Treatment6▲ 3.3×12 topics
- Prognostic Factors5▲ 7.6×7 topics
- Endoscopic Resection4▲ 32×2 topics
- Precision Medicine4▲ 6.8×6 topics
- Bladder Cancer4▲ 83×1 topic
- Genomic Profiling4▲ 30×2 topics
- Urothelial Carcinoma4▲ 71×1 topic
- Cardiac Imaging4▲ 25×3 topics
- Meta-Analysis4▲ 5.2×2 topics
- Cardiomyopathies4▲ 102×1 topic
- Dilated Cardiomyopathy4▲ 43×2 topics
- Myosin4▲ 102×1 topic
- ALK Inhibitors4▲ 45×1 topic
- EGFR Mutations4▲ 45×1 topic
- Monoclonal Antibodies4▲ 30×3 topics
- Heart Failure4▲ 6.0×6 topics
- Lymphoma4▲ 16×2 topics
- Adjuvant Therapy3▲ 20×2 topics
- Preoperative Chemoradiotherapy3▲ 32×2 topics
- Tumor Staging3▲ 23×2 topics
- Chemoradiation3▲ 37×2 topics
- Barrett's Esophagus3▲ 59×1 topic
- Esophageal Carcinoma3▲ 59×1 topic
Which research topics does Bristol-Myers Squibb (United Kingdom) publish most on?
By volume in 2022–2025: Health Systems, Economic Evaluations, Quality of Life, Economic and Financial Impacts of Cancer, Cancer Immunotherapy and Biomarkers and Bladder and Urothelial Cancer Treatments.
Area is fractional works; colour is the subfield each topic belongs to.
- 1 Health Systems, Economic Evaluations, Quality of Life Economics and Econometrics 10 works
- 2 Economic and Financial Impacts of Cancer Economics and Econometrics 7 works
- 3 Cancer Immunotherapy and Biomarkers Oncology 6 works
- 4 Bladder and Urothelial Cancer Treatments Surgery 4 works
- 5 Cardiomyopathy and Myosin Studies Cardiology and Cardiovascular Medicine 4 works
- 6 Lung Cancer Treatments and Mutations Pulmonary and Respiratory Medicine 4 works
- 7 Esophageal Cancer Research and Treatment Surgery 3 works
- 8 CAR-T cell therapy research Oncology 3 works
- 9 Lung Cancer Diagnosis and Treatment Pulmonary and Respiratory Medicine 2 works
- 10 Drug Solubulity and Delivery Systems Pharmaceutical Science 2 works
How open and international is its research?
Against the world’s own shares — the tick on each track. Both are shares of its output, so they sit on one scale and can be read against each other as well as against the world.
World: 28% of research is openly available.
World: 19% is written across borders.
How has Bristol-Myers Squibb (United Kingdom)'s research output changed?
Output in 2018–2022 was 97% higher than in 2013–2017.
The same series as a ribbon — one cell per year, darker for more. The line above answers how much; this answers when.
Other research institutions in Moreton
Research measures only: rankings here say nothing about teaching, admissions or student experience. Comparable institutions and collaboration partners are in the interactive view on the map.